NCT00802568View on ClinicalTrials.gov

Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2011

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

BIOLOGICAL

anti-thymocyte globulin

DRUG

busulfan

DRUG

fludarabine phosphate

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

nonmyeloablative allogeneic hematopoietic stem cell transplantation

Trial Locations (1)

13273

Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille

All Listed Sponsors

lead

Institut Paoli-Calmettes

OTHER

NCT00802568 - Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment | Biotech Hunter | Biotech Hunter